메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Silvio Danese (Istituto Clinico Humanitas) Rupa Banerjee (Inflammatory Bowel Diseases ClinicAsian Institute of Gastroenterology) JR Fraser Cummings (Southampton General Hospital) Iris Dotan (Rabin Medical Center) Paulo G Kotze (Hospital Universitário Cajuru Pontifical Catholic University of Paraná Curitiba) Rupert Wing Loong Leong (Concord Hospital Sydney) Kristine Paridaens (Ferring Pharmaceuticals Saint-Prex Switzerland) Laurent Peyrin-Biroulet (Nancy University Hospital) Glyn Scott (East Kent Hospitals Trust Canterbury UK) Gert Van Assche (UZ Leuven Leuven) Jan Wehkamp (University Hospital Tuebingen) Jesús K Yamamoto-Furusho (Instituto Nacional de Ciencias Médicas y Nutrición Mexico City)
저널정보
대한장연구학회 Intestinal research Intestinal research Vol.16 No.4
발행연도
2018.1
수록면
522 - 528 (7page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Symptomatic ulcerative colitis (UC) can be a chronic, disabling condition. Flares in disease activity are associated with manyof the negative impacts of mild-to-moderate UC. Rapid resolution of flares can provide benefits to patients and healthcaresystems. i Support Therapy–Access to Rapid Treatment (iSTART) introduces patient-centered care for mild-to-moderate UC. iSTART provides patients with the ability to self-assess symptomology and self-start a short course of second-line treatmentwhen necessary. An international panel of experts produced consensus statements and recommendations. These were informedby evidence from systematic reviews on the epidemiology, mesalazine (5-ASA) treatment, and patient use criteria forsecond-line therapy in UC. Optimized 5-ASA is the first-line treatment in all clinical guidelines, but may not be sufficient toinduce remission in all patients. Corticosteroids should be prescribed as second-line therapy when needed, with budesonideMMX® being a preferred steroid option. Active involvement of suitable patients in management of UC flares has the potentialto improve therapy, with patients able to show good accuracy for flare self-assessment using validated tools. There is a place inthe UC treatment pathway for an approach such as iSTART, which has the potential to provide patient, clinical and economicbenefits. (Intest Res 2018;16:522-528)

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0